Studies such as the DCCT have shown that intensive insulin therapy can improve glycaemic control and thereby reduce the risk of micro- and macrovascular complications faced by patients with Type 1 diabetes [1,2]. This evidence concerns the gene INS and type 1 diabetes mellitus.